Diagnosis and treatment of lipodystrophy: a step‑by‑step approach

Abstract

Aim : Lipodystrophy syndromes are rare heterogeneous disorders characterized by defciency of adipose tissue, usually a decrease in leptin levels and, frequently, severe metabolic abnormalities including diabetes mellitus and dyslipidemia. Purpose : To describe the clinical presentation of known types of lipodystrophy, and suggest specifc steps to recognize, diagnose and treat lipodystrophy in the clinical setting. Methods : Based on literature and in our own experience, we propose a stepwise approach for diagnosis of the diferent subtypes of rare lipodystrophy syndromes, describing its more frequent co-morbidities and establishing the therapeutical approach. Results : Lipodystrophy is classifed as genetic or acquired and by the distribution of fat loss, which can be generalized or partial. Genes associated with many congenital forms of lipodystrophy have been identifed that may assist in diagnosis. Because of its rarity and heterogeneity, lipodystrophy may frequently be unrecognized or misdiagnosed, which is concerning because it is progressive and its complications are potentially life threatening. A basic diagnostic algorithm is proposed. Efective management of lipodystrophy includes lifestyle changes and aggressive, evidence-based treatment of comorbidities. Leptin replacement therapy (metreleptin) has been found to improve metabolic parameters in many patients with lipodystrophy. Metreleptin is approved in the United States as replacement therapy to treat the complications of leptin defciency in patients with congenital or acquired generalized lipodystrophy and has been submitted for approval in Europe. Conclusions : Here, we describe the clinical presentation of known types of lipodystrophy, present an algorithm for diferential diagnosis of lipodystrophy, and suggest specifc steps to recognize and diagnose lipodystrophy in the clinical setting.